Vivos Therapeutics Sees 212% Surge in Nevada Sleep Apnea Referrals — Vivos Therapeutics, Inc.

Event summary

Vivos Therapeutics reported a 212% increase in new OSA patient referrals at its Nevada centers over the past six weeks.
Average weekly referrals have risen nearly five-fold since June 1, 2026.
The company opened an 8,100 sq. ft. state-of-the-art facility in Henderson, Nevada, on August 27, 2026.
Henderson operations recorded highest total collections in two of the past three months.
CEO Kirk Huntsman cited recent operational and personnel changes as drivers of growth.

The big picture

Vivos Therapeutics is capitalizing on growing awareness of obstructive sleep apnea (OSA) with a 212% surge in patient referrals at its Nevada centers. The expansion of its Henderson facility and recent operational changes position the company to capture a larger share of the underserved OSA market. With FDA-cleared devices targeting both adults and children, Vivos is well-positioned to challenge traditional OSA treatments, though execution risks remain.

What we're watching

Revenue Conversion: Whether the surge in referrals will translate into sustained revenue growth as patients progress through treatment.
Operational Scaling: The pace at which Vivos can scale its Nevada operations to handle increased patient volume.
Market Positioning: How Vivos' non-invasive OSA treatments will compete against legacy solutions like CPAP.